http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e755c1d4246159a69fbd31d2482312a
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Richardson |
| name | Paul Richardson |
| given-name | Paul |
| organization-name | Department of Pathology, Johns Hopkins University School of Medicine, Baltimore,MD; Joint Genome Institute, Walnut Creek, California The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute; and Consultant Hepatologist, Royal Liverpool University Hospital Authors' Affiliations: 1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 2Institute for Nutritional Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China, and Children's Hospital, Boston, Massachusetts; and 3Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Medicinal Sciences, Pfizer Inc, La Jolla, CA, USA Pfizer Global Research and Development, 10777 Science Center Drive (CB2), San Diego, California 92121, United States Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, 450 Brookline Avenue, Dana 1B02, Boston, MA 02115, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Harvard Medical School Boston MA USA; Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana–Farber Cancer Institute Boston MA USA Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02215, USA DOE Joint Genome Institute, Walnut Creek, CA 94598, USA.; Genomics and DOE Joint Genome Institute, Production Genome Facility, Walnut Creek, California 94598; Lawrence Berkeley National Laboratory, Berkeley, California 94720 Functional Genomics Division, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Authors' Affiliations: 1Beth Israel Deaconess Medical Center; 2Dana Farber Cancer Institute; 3Massachussetts General Hospital, Boston, Massachusetts; and 4Rambam Medical Center, Haifa, Israel From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 1DOE Joint Genome Institute, Walnut Creek, California, USA The TSC1 Consortium:; M. van Slegtenhorst, R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, S. Verhoef, D. Lindhout, A. van den Ouweland, D. Halley, Department of Clinical Genetics, Erasmus University and University Hospital, Rotterdam, Netherlands.; J. Young, M. Burley, S. Jeremiah, K. Woodward, J. Nahmias, M. Fox, R. Ekong, J. Wolfe, S. Povey, MRC Human Biochemical Genetics Unit and Galton Laboratory, University College of London, London NW1 2HE, UK.; J. Osborne, University of Bath, Bath BA2 7AY, UK.; R. G. Snell, J. P. Cheadle, A. C. Jones, M. Tachataki, D. Ravine, J. R. Sampson, Institute of Medical Genetics, University of Wales College of Medicine, Cardiff CF4 4XN, Wales, UK. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool UK LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Pfizer Medicinal Chemistry 10770 Science Center Drive San Diego CA 92121 USA From the Department of Medicine, Division of Biostatistics, Dana-Farber Cancer Institute; and the Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Dana-Farber Cancer Institute, Boston, MA; and Sheffield Hallam University, Sheffield, UK Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115. Medical Oncology, Dana‐Farber Cancer Institute Harvard Medical School Boston, Massachusetts Department of Gastroenterology and Hepatology Liverpool University Foundation Hospitals NHS Trust Liverpool UK The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Joint Genome Institute, Walnut Creek, CA 94598; Liver Unit, Royal Liverpool Hospital, Liverpool, UK; Johns Hopkins University, Baltimore, Maryland Medicine Design, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center Dana Farber Cancer Institute, Harvard Medical School Boston Massachusetts USA From the University of Rochester (J.S.G., M.P.M., R.H.D.), NY; MetroHealth Medical Center (J.B.), Case Western Reserve University, Cleveland, OH; University of Milano-Bicocca (G.C.), Monza, Italy; MD Anderson Cancer Center (P.M.D.), Houston, TX; Milkin Institute School of Public Health (S.E.), George Washington University, Washington, DC; Division of Oncology Products (L.H.), US Food and Drug Administration, Silver Spring; National Institutes of Health (A.O.), Bethesda, MD; Virginia Commonwealth... From The Jerome Lipper Multiple Myeloma Center, the Department of Medical Oncology, Cancer Biology, Boston Veteran Affairs Healthcare System and Biostatistical Sciences, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada Liverpool UK The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; Department of Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. U.S. Department of Energy Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA. Departments R47S AP9A, R46Y AP10, and R460 AP10, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 From the Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Research & Development, AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States Department of Pathology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Authors' Affiliations: 1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 2Department of Oncology/Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm; and 3Oncopeptides AB, Karolinska Institutet Science Park, Solna, Sweden From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; the 1st Department of Internal Medicine, Fukuoka University, Nanakuma Jonan Fukuoka, Japan; and the Department of Dermatology, Emory University School of Medicine, Atlanta, GA. Worldwide Research and Development, Pfizer Inc., San Diego, California 92121, United States Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, MA; Royal Liverpool University National Health Service Trust,Liverpool,United Kingdom The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Department of Experimental Haematology, The Royal London School of Medicine, London, United Kingdom. United States Department of Energy Joint Genomic Institute, Walnut Creek, CA 94598; and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; School of Medicine Johns Hopkins University Baltimore MD USA Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Hepatology, Royal Liverpool University Hospital, L7 8XP, U.K. Department of Chemistry and Biomolecular Sciences University of Ottawa 10 Marie Curie Ottawa ON K1N 6N5 Canada 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts and Digestive Diseases Unit Liverpool University Hospitals NHS Foundation Trust Liverpool UK Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA 1Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598 The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, and U.S. DoE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Department of Medicine, Harvard Medical School, Boston, MA. Departement of Hepatology, Royal Liverpool University Hospital, Liverpool, United Kingdom; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Harvard Medical School Boston, Massachusetts, USA. 1Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, California, USA Department of Chemistry, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121; Department of Hepatology, Royal Liverpool University Hospital, Liverpool, U.K. Jerome Lipper Multiple Myeloma Center Dana‐Farber Cancer Institute Boston MA USA Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA Department of Chemistry and Biomolecular Sciences and Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa, OntarioK1N 6N5, Canada Harvard Medical School, and Dana-Farber Cancer Institute's Jerome Lipper Multiple Myeloma Center, USA. Oncology Medicinal Chemistry, WRD, Pfizer-La Jolla, USA 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts and 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; the Department of Medicine, Harvard Medical School, Boston, MA; and Novartis Institutes for Biomedical Research, Oncology Research, East Hanover, NJ. DOE Joint Genome Institute Production Genome Facility, Walnut Creek, California 94598; Lawrence Berkeley National Laboratory, Berkeley, California 94720 Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA, USA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center; Department of Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School; Boston MA USA Department of Hepatology The Royal Liverpool University Hospital Liverpool UK Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dana‐Farber Cancer Institute Boston Massachusetts USA From Weill Cornell Medicine, New York, New York; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington; University of California, Los Angeles, Los Angeles, California; University of Michigan, Ann Arbor, Michigan; Johns Hopkins University School of Medicine, Baltimore, Maryland; University of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of North Carolina, Chapel Hill, North Carolina;; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; ViiV Healthcare, Durham, North Carolina; Gilead Sciences, Foster City, California; Case Western Reserve University, Cleveland, Ohio; The George Washington University and FHI 360, Washington, DC; Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; University of Puerto Rico School of Medicine, San Juan, Puerto Rico;; Rutgers New Jersey Medical School, Newark, New Jersey; West Virginia University, Morgantown, West Virginia; and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Pfizer Medicinal Chemistry; 10578 Science Center Drive; San Diego; USA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts; and Pfizer Global Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States Gastroenterology The Royal Liverpool University Hospital Liverpool UK Department of Hepatology, Royal Liverpool University Hospital, Liverpool, United Kingdom; From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, VA Boston Healthcare System and Harvard Medical School, Boston, MA; the Division of Hematology, Mayo Clinic, Rochester, MN; and Celgene Corporation, Warren, NJ. Jerome Lipper Multiple Myeloma Center, Division of Hematologic Neoplasia, Harvard Medical School, and Dana-Farber Cancer Institute, Boston, MA Laboratoire des Symbioses Tropicales et Méditerranéennes, Unité mixte recherche (UMR) 113, Institut de Recherche pour le Développement, Centre de Coopération International en Recherche Agronomique pour le Développement, AGRO Montpellier, Institut National de la Recherche Agronomique, Université Montpellier 2, TA A-82/J, Campus de Baillarguet, 34398 Montpellier Cedex 5, France.; Genoscope, CNRS–UMR 8030, Atelier de Génomique Comparative, 2 rue Gaston Crémieux BP5706, 91057 Evry Cedex, France.; Genoscope, Centre National de Séquençage, 2 rue Gaston Crémieux BP5706, 91057 Evry Cedex, France.; Department of Soil, Water, and Climate; BioTechnology Institute; and Microbial and Plant Genomics Institute, University of Minnesota, 1991 Upper Buford Circle, 439 BorH, St. Paul, MN, 55108, USA.; Commissariat à l'Energie Atomique (CEA) Cadarache, Direction des Sciences du Vivant, Institut de Biologie Environnementale et Biotechnologie, Service de Biologie Végétale et de Microbiologie Environnementale, Laboratoire de Bioénenergétique Cellulaire (DSV/IBEB/SBVME/LBC), UMR 6191 CNRS/CEA/Université Aix-Marseille, Saint-Paul-lez-Durance, F-13108 France. Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA 2Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome,... From the Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA; and Celgene Corporation, Warren, NJ. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Dana‐Farber Cancer Institute Boston MA USA Jerome Lipper Myeloma Center, Division of Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; 2DOE Joint Genome Institute, Walnut Creek, California, USA Johns Hopkins University, Baltimore, Maryland. Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Energy Joint Genome Institute, Walnut Creek, California; Lawrence Berkeley National Laboratory, Berkeley, California From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA. 2Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology Division of Hematologic Malignancies Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Jerome Lipper Multiple Myeloma Center, Harvard Medical School, and Dana-Farber Cancer Institute, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Chemistry, Dartmouth College, Hanover, NH; and Department of Pharmacology, Dartmouth Medical School, Hanover, NH. Departments of Biology, Boston University, Boston, Massachusetts 02215 Liver Unit, Royal Liverpool Hospital, Liverpool, United Kingdom. School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA 1The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School and 4Dana Farber Cancer Institute, Boston, Massachusetts. Philippe Moreau, Florence Caillon, Caroline Bodet-Milin, Aurelie Gaultier, Jean-Michel Nguyen, Benoit Dupas, Eric Frampas, and Françoise Kraeber-Bodere, University Hospital, Nantes; Michel Attal, University Hospital, Toulouse; Denis Caillot, University Hospital, Dijon; Margaret Macro, University Hospital, Caen; Lionel Karlin, University Hospital, Lyon; Laurent Garderet, University Hospital Saint-Antoine, Paris; Thierry Facon, University Hospital, Lille; Lotfi Benboubker, University Hospital, Tours;... Johns Hopkins School of Medicine, Department of Pathology, 600North Wolfe St., Baltimore, MD 21287, United States. Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. DOE Joint Genome Institute, Walnut Creek, California 94598 From Science Research Laboratory Inc, Somerville, MA; the Center for Regenerative Medicine and Technology, Massachusetts General Hospital; and the Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Pfizer Medicinal Chemistry, 10578 Science Center Drive, San Diego, California 92121, United States Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts; Department of Hepatology, Royal Liverpool Hospital, Liverpool, UK Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Laboratoire de Rhéologie et procédés, UJF/INPG/CNRS, BP 53, Domaine universitaire, 38041 Grenoble, France Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA. paul_richardson@dfci.harvard.edu. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Dana-Farber Cancer Institute, Boston, MA Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115; Broad Institute of Harvard University and Massachusetts Institute of Technology, 320 Charles Street, Cambridge, MA 02141; and Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138 Departments of Cancer Research and Advanced Technology, Abbott Laboratories, Abbott Park, Illinois 60064-6117 Dana Farber Cancer Institute, Boston, Massachusetts 02115; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA U.S. Department of Energy Joint Genome Institute, Walnut Creek, CA 94598; Department of Energy, Joint Genome Institute, Walnut Creek, California 94598 From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA. Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. La Jolla Laboratories, Pfizer, Inc., 10770 Science Center Drive, San Diego, California 92121, United States, and WuXi App Tec Co., Shanghai, China From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA. Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Pfizer Medicinal Chemistry 10578 Science Center Drive San Diego CA 92121 USA Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA |
Incoming Links
Total number of triples: 577.